文献速递消化系统肿瘤

氟嘧啶类、伊立替康与贝伐珠单抗序贯对比联合治疗转移性结直肠癌:随机对照研究 XELAVIRI(AIO KRK0110)

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
PubMed 文献 · J Clin Oncol · 2018-11-02

XELAVIRI III 期随机对照试验比较初治转移性结直肠癌先予氟嘧啶类联合贝伐珠单抗、进展后加用伊立替康(A 组)与起始即用氟嘧啶类联合伊立替康及贝伐珠单抗(B 组)的策略。主要终点策略失败时间(TFS)的非劣效性未获证实(HR 0.86,90%CI 0.73–1.02);RAS/BRAF 野生型患者从起始联合化疗获益(HR 0.61,90%CI 0.46–0.82),RAS 突变型患者两组结果相当。

要点

  • TFS 非劣效性未获证实:HR 0.86(90%CI 0.73–1.02)。
  • RAS/BRAF 野生型患者起始联合化疗更优(HR 0.61,90%CI 0.46–0.82)。
  • RAS 突变型患者序贯升级化疗结果相当(HR 1.09,90%CI 0.81–1.46)。

核心结论

  • 序贯升级治疗对比起始联合化疗在 TFS 上未能证实非劣效性。
  • RAS 状态可能有助于指导治疗:RAS/BRAF 野生型肿瘤患者起始联合化疗明显更优,而 RAS 突变型患者序贯升级化疗似乎提供相当的结果。

研究设计与样本

  • 1:1 随机对照 III 期试验,比较氟嘧啶类联合贝伐珠单抗后进展时加用伊立替康(A 组)与起始即用氟嘧啶类联合伊立替康及贝伐珠单抗(B 组)。
  • 全分析集共 421 例随机分组患者,A 组 n=212,B 组 n=209;中位年龄分别为 71 岁和 69 岁。
  • 主要疗效终点为策略失败时间(TFS);非劣效界值设为 0.8,采用 90%CI、70% 把握度、单侧 α=.05。

主要发现

  • TFS 非劣效性未获证实:HR 0.86(90%CI 0.73–1.02)。
  • RAS/BRAF 野生型肿瘤患者从联合化疗获益:HR 0.61(90%CI 0.46–0.82;P=.005)。
  • RAS 突变型肿瘤患者未显示获益:HR 1.09(90%CI 0.81–1.46;P=.58);研究组与 RAS 状态交互作用的 Cox 模型 P=.03。
  • 总生存获得可比结果。

关键数值与推荐

  • TFS 非劣效界值为 0.8,采用 90%CI、70% 把握度、单侧 α=.05。
  • RAS/BRAF 野生型肿瘤患者联合化疗 HR 0.61(90%CI 0.46–0.82;P=.005)。
  • RAS 突变型肿瘤患者 HR 1.09(90%CI 0.81–1.46;P=.58)。
  • 研究组与 RAS 状态交互作用 Cox 模型 P=.03。

临床怎么用

  • 原文结论指出 RAS 状态可能有助于指导治疗:RAS/BRAF 野生型肿瘤患者起始联合化疗明显更优,RAS 突变型患者序贯升级化疗似乎提供相当的结果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The XELAVIRI trial investigated the optimal treatment strategy for patients with untreated metastatic colorectal cancer. We tested the noninferiority of initial treatment with a fluoropyrimidine plus bevacizumab, followed by the addition of irinotecan at first progression (arm A) versus upfront use of fluoropyrimidine plus irinotecan plus bevacizumab (arm B) in a 1:1 randomized, controlled phase III trial. METHODS: The primary efficacy end point was time to failure of the strategy (TFS). Given a 90% CI, a power of 70%, and a one-sided α of .05, the margin for noninferiority was set at 0.8. In the case of demonstrated noninferiority of TFS, an analysis of symptomatic toxicities during TFS would define the superior strategy. Secondary end points included the effect of molecular subgroups on efficacy parameters. RESULTS: A total of 421 randomly assigned patients (arm A: n = 212; arm B: n = 209) formed the full analysis set. Median age was 71 and 69 years, respectively. Noninferiority of TFS was not shown (hazard ratio [HR], 0.86; 90% CI, 0.73 to 1.02). In detail, patients with RAS/BRAF wild-type tumors benefitted from combination chemotherapy (HR, 0.61; 90% CI, 0.46 to 0.82; P = .005), whereas patients with RAS mutant tumors (HR, 1.09; 90% CI, 0.81 to 1.46; P = .58) did not (Cox model for interaction of study arm and RAS status: P = .03). Comparable results were obtained for overall survival. CONCLUSION: Noninferiority of sequential escalation therapy compared with initial combination chemotherapy could not be demonstrated for TFS. RAS status may be important to guide therapy as treatment of patients with upfront combination therapy was clearly superior in RAS/BRAF wild-type tumors, whereas sequential escalation chemotherapy seems to provide comparable results in patients with RAS mutant tumors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Modest DP, Fischer von Weikersthal L, Decker T, et al. Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110). J Clin Oncol. 2018. PMID: 30388045. doi:10.1200/JCO.18.00052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。